Mar 06, 2023 6:30am EST Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update
Mar 06, 2023 6:00am EST Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
Feb 22, 2023 8:00am EST Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023
Jan 09, 2023 8:00am EST Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma
Dec 23, 2022 1:20pm EST Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma
Nov 18, 2022 8:00am EST Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent
Nov 08, 2022 7:00am EST Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers
Oct 27, 2022 12:27pm EDT Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022
